OpenAI acquires Orchestra Bio to speed drug development with AI agents
Dr_Singularity · x · 2026-10-21
OpenAI announced the acquisition of Orchestra Bio, an AI-powered drug development platform, planning to combine its drug development agents with Rosalind AI to accelerate the entire journey from scientific discovery to new medicines reaching patients. The company notes new drugs take roughly 10–15 years from target discovery to FDA approval, often fragmented across disconnected systems and partners — and argues AI has reached an inflection point to take on these specialized workflows.
Related event: OpenAI Acquires Orchestra Bio to Bring AI Agents into Drug Development(13 posts)→
More from Companies & People
- AI creator Bilawal Sidhu crosses 1M followers on TikTok with 9.8M likes — bilawalsidhu · 2026-10-21
- Jensen Huang: every company will have two factories, one real and one digital — round · 2026-10-21
- Palo Alto, not SF, is now the hottest neighborhood for new AI labs — infoxiao · 2026-10-21
- Ex-Twitter engineer credits X's growth to the long-delayed Android rewrite — Scobleizer · 2026-10-21
- Walden Robotics CTO joins Long Horizon panel on large behavior models with Rodney Brooks — adnothing · 2026-10-21
- Grok Bot's first OOH ads hit NYC, pitching AI teammates that get work done — soleio · 2026-10-21